An analysis of relative costs and potential benefits of different policies for antenatal screening for β thalassaemia trait and variant haemoglobins

Journal of Clinical Pathology

Volumn 52, Issue 9, 1999, Pages 697-700

  Phelan, L ^a   Bain, Barbara J ^a   Roper, D ^b   Jury, C ^b   Bain, K ^c  

^a ST MARY S HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EAST LONDON   (United Kingdom)

Author keywords

Antenatal screening; Haemoglobinopathy; Thalassaemia

Indexed keywords

HEMOGLOBIN A2;

ARTICLE; BETA THALASSEMIA; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC VALUE; ETHNIC GROUP; HEALTH CARE POLICY; HEMOGLOBINOPATHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; MEAN CORPUSCULAR HEMOGLOBIN; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0032833488     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.9.697     Document Type: Article

References (3)

1. The Thalassaemia Working Party of the BCSH General Haematology Task Force. Guidelines for the investigation of the α and β thalassaemia traits. J Clin Pathol 1994;47:289-95.
2. The Standing Medical Advisory Committee on Sickle Cell, Thalassaemia and other Haemoglobinopathies. Report of a working party of the Standing Medical Advisory Committee on Sickle Cell, Thalassaemia, and other Haemoglobinopathies. London: HMSO, 1993.
3. Bain BJ, Chapman C, on behalf of the UK Forum for Haemoglobin Disorders. A survey of current United Kingdom practice for antenatal screening for inherited disorders of globin chain synthesis. J Clin Pathol 1998;51:382-9.